AKTX News

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Hyaluronic Acid Market Forecasts Report 2025-2030: Opportunities Driven by Demand for Non-surgical Cosmetic Procedures and Interest in Anti-aging Solutions

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors